Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction

dc.contributor.authorChandler, Emmanuel
dc.contributor.authorDing, Lili
dc.contributor.authorGorbach, Pamina
dc.contributor.authorFranco, Eduardo L.
dc.contributor.authorBrown, Darron A.
dc.contributor.authorWiddice, Lea E.
dc.contributor.authorBernstein, David I.
dc.contributor.authorKahn, Jessica A.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2019-09-03T18:58:29Z
dc.date.available2019-09-03T18:58:29Z
dc.date.issued2018-07
dc.description.abstractPURPOSE: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status. METHODS: Young men were recruited from clinical sites from 2013 to 2015, completed a survey, and were tested for 36 anogenital HPV types. We determined factors associated with ≥1 HPV type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, vaccinated and unvaccinated participants, using multivariable regression. RESULTS: Mean age was 21.5 years and 26% had received at least one HPV vaccine dose. HPV prevalence was lower in vaccinated versus unvaccinated young men (50.5% vs. 62.6%, p = .03). HPV positivity was discordant by anogenital site. At both sites, 59.4% were positive for ≥1 HPV type and 26.0% for ≥1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥1 HPV type among all participants were frequency of oral sex (odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.00-3.24), recent smoking (OR = 1.84, CI = 1.17-2.90), and sexually transmitted infection history (OR = 1.56, CI = 1.02-2.38). Factors associated with vaccine-type HPV among all participants were white versus black race (OR = 1.91, CI = 1.10-3.34) and gonorrhea history (OR = 2.52, CI = 1.45-4.38); among vaccinated participants were private versus Medicaid insurance (OR = 5.6, CI = 1.46-20.4) and private versus no insurance (OR = 15.9, CI = 3.06-83.3); and among unvaccinated participants was gonorrhea history (OR = 1.83, CI = 1.03-3.24). CONCLUSIONS: Anogenital HPV prevalence was high and vaccination rates low among young men 2-4 years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating according to national guidelines.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationChandler, E., Ding, L., Gorbach, P., Franco, E. L., Brown, D. A., Widdice, L. E., … Kahn, J. A. (2018). Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 63(1), 43–49. doi:10.1016/j.jadohealth.2018.01.005en_US
dc.identifier.urihttps://hdl.handle.net/1805/20758
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.jadohealth.2018.01.005en_US
dc.relation.journalThe Journal of Adolescent Healthen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectHuman papillomavirusen_US
dc.subjectSexually transmitted infectionsen_US
dc.subjectVaccinesen_US
dc.subjectYoung menen_US
dc.titleEpidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introductionen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms973170.pdf
Size:
106.36 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: